A biotechnology company focused on developing and commercializing vaccines, with its primary marketed product being HEPLISAV-B, a hepatitis B vaccine for adults. The company also develops and licenses its CpG 1018 adjuvant technology, which is used to enhance immune responses in vaccines developed w...
1 member of Congress has disclosed 1 trade in Dynavax Technologies Holdings Corp (DVAX), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-08-21 | Sharice Davids | sell | $15K – $50K |